You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest The Cure Articles
Popular The Cure Articles
Highly Recommended The Cure Articles
Send a link to this page to your friends and colleagues.
This press release is an announcement submitted by sanofi-aventis, and was not written by Diabetes Health.
IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.
Leading European experts from 14 academic institutions, 8 pharmaceutical research organizations and 1 biotech company in the area of pancreatic ss-cells (= the body's own insulin producing cells) officially launched the IMIDIA project. The project is supported by the Innovative Medicines Initiative (IMI). IMI is a unique Public Private Partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations / EFPIA) and the European Union. The EU contributes a total of EUR 1 billion over ten years, which is matched in-kind by the EFPIA member companies.
IMIDIA is an important stepping stone in the development of better tools, biomarkers and understanding to enable the development of ss-cell medicines - a key to an ultimate long-term vision: the cure for diabetes. This pandemic disease of the 21st century currently affects 285 million people worldwide. It is anticipated that this number will rise sharply to affect 439 million people worldwide by 2030 in particular spreading to the younger population.
IMIDIA is a unique collaboration of leading research groups in Europe focusing on the necessary innovation tightly coupled with the applications and evaluation of these results to develop new diagnostics, prognostics and therapeutics. Around 100 researchers operating in 6 different scientific work packages will focus on novel approaches e.g. imaging biomarkers, systems biology and pathway analysis with the goal of developing patient relevant disease models in vitro and in vivo as well as biomarkers to monitor disease progression and treatment.
"It has been fascinating to see how a powerful consortium has been formed starting from the different worlds of academic research and the pharmaceutical industry research organizations," Werner Kramer from sanofi-aventis, Bernard Thorens from University of Lausanne and Alain Ktorza from Servier, the "Triumvirate" coordinating IMIDIA, agree. "Guided by a sustainable win-win situation for all participants, the collaborative spirit coupled with the free flow of information and data within the IMIDIA project teams will support us - the IMIDIA team - in our endeavour to reach these ambitious goals."
The IMIDIA team, led by sanofi-aventis, Servier and the University of Lausanne is working on the generation of novel, patient centric tools, biomarkers, and fundamental knowledge on ss-cell organization to accelerate the path to improved diabetes management.
The scientific program aims at delivering:
IMIDIA participants are AstraZeneca, Boehringer Ingelheim, the French Atomic Energy Commission (CEA), Hannover Medical School (MHH), Imperial College London, Lilly, the National Centre for Scientific Research (CNRS), the National Institute of Health and Medical Research (INSERM), Novartis, Novo Nordisk, Roche, sanofi-aventis, Sarl Endocells, Servier, SIB Swiss Institute of Bioinformatics, Vrije University of Brussels, Dresden University of Technology, University of Geneva, University of Lausanne, University Paris Diderot, University of Pisa.
The close collaboration of academic teams, pharmaceutical companies and biotechs is providing unique levels of expertise and is forming a strong basis to reach the IMIDIA project goals.
For further details - please visit: http://www.imidia.org
The Innovative Medicines Initiative is a unique Public Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
IMI's overall goal is to make Europe again the world leader in pharmaceutical research for the benefit of the economy and society, by removing research bottlenecks in the current drug development process.
For further details - please visit: http://imi.europa.eu/
* * *
Source: Sanofi-aventis R&D
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.